William Blair Equities Analysts Raise Earnings Estimates for Repligen Co. (RGEN)

Repligen Co. (NASDAQ:RGEN) – Investment analysts at William Blair raised their Q1 2019 earnings estimates for Repligen in a research report issued to clients and investors on Wednesday, June 27th. William Blair analyst A. Murphy now expects that the biotechnology company will earn $0.18 per share for the quarter, up from their prior estimate of $0.17. William Blair also issued estimates for Repligen’s Q3 2019 earnings at $0.21 EPS and Q4 2019 earnings at $0.22 EPS.

A number of other analysts have also recently weighed in on the stock. ValuEngine raised shares of Repligen from a “hold” rating to a “buy” rating in a report on Thursday. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 19th. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, May 26th. Finally, TheStreet raised shares of Repligen from a “c” rating to a “b-” rating in a report on Tuesday, March 13th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $44.57.

RGEN stock opened at $46.80 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 10.25 and a current ratio of 12.22. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $47.26. The stock has a market capitalization of $1.99 billion, a P/E ratio of 63.10, a PEG ratio of 3.03 and a beta of 0.90.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.02. The company had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $43.88 million. Repligen had a net margin of 18.48% and a return on equity of 6.06%. The firm’s revenue was up 46.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.15 earnings per share.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 1,932 shares of the firm’s stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $44.31, for a total transaction of $85,606.92. Following the transaction, the director now owns 7,354 shares of the company’s stock, valued at approximately $325,855.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nicolas Barthelemy sold 26,500 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The shares were sold at an average price of $40.54, for a total transaction of $1,074,310.00. Following the transaction, the director now directly owns 27,988 shares in the company, valued at approximately $1,134,633.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 303,531 shares of company stock worth $12,561,406. 1.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. increased its stake in Repligen by 2.3% during the 1st quarter. Prudential Financial Inc. now owns 63,565 shares of the biotechnology company’s stock valued at $2,300,000 after buying an additional 1,450 shares during the period. Legal & General Group Plc increased its stake in Repligen by 2.0% during the 1st quarter. Legal & General Group Plc now owns 77,094 shares of the biotechnology company’s stock valued at $2,771,000 after buying an additional 1,527 shares during the period. Victory Capital Management Inc. increased its stake in Repligen by 38.9% during the 1st quarter. Victory Capital Management Inc. now owns 5,755 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 1,612 shares during the period. Profund Advisors LLC increased its stake in Repligen by 29.2% during the 1st quarter. Profund Advisors LLC now owns 7,174 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 1,620 shares during the period. Finally, Glen Harbor Capital Management LLC increased its stake in Repligen by 21.7% during the 1st quarter. Glen Harbor Capital Management LLC now owns 9,520 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 1,700 shares during the period. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply